Skeletal Muscle. Dec/31/2010; 1: 19-19

Published online May/3/2011

PMID: 21798096

PMC: 3156642

doi: 10.1186/2044-5040-1-19

Role of TGF-β signaling in inherited and acquired myopathies

Tyesha N Burks

Ronald D Cohn

Abstract

Introduction

The transforming growth factor-beta (TGF-β) superfamily plays a crucial role in normal physiology and pathogenesis in a number of tissues. It is important to emphasize that downstream effects of this signaling cascade are often tissue-specific, thereby dictating which target genes will be activated in response to the transduction signal. Given its multifaceted effects in different tissues, deregulation of TGF-β signaling cascades can lead to a multitude of developmental defects and/or disease [1]. Several members of the TGF-β family have been shown to play important roles in regulating muscle growth and atrophy. The most extensively characterized ligands, in terms of the effects on skeletal muscle, are TGF-β1, mitogen-activated protein kinases (MAPKs), and myostatin. In this review, we focus on these signaling molecules in normal homeostasis and pathological conditions affecting skeletal muscle and describe the therapeutic avenues that have recently been explored to target the TGF-β signaling cascade.

Overview of the TGF-β superfamily signaling cascade

The TGF-β superfamily of cytokines consists of a variety of signaling molecules including isoforms of TGF-β (1 to 3), bone morphogenic proteins (BMPs 1 to 20), growth and differentiation factors (GDFs), activins (A and B), inhibins (A and B), nodal, leftys (1 and 2), and Mullerian inhibiting substance [1]. They are generally divided into two branches defined by the utilization of receptor Smads (R-Smads): the TGF-β branch, consisting of TGF-β, activin, Nodal, and myostatin (GDF-8), signals through R-Smads 2 and 3 and the BMP branch, consisting of BMPs and other GDFs, signals through R-Smads 1, 5 and 8. This superfamily is known to be involved in embryonic development, adult tissue homeostasis, and disease pathogenesis. Specifically, it has been shown to control proliferation, differentiation, apoptosis, migration, extracellular matrix (ECM) remodeling, immune functions, and tumor invasion/metastasis [2].

TGF-β1 is synthesized as a precursor that is cleaved intracellularly into an inactive complex consisting of the mature TGF-β1 non-covalently bound to the portion of the precursor peptide termed the latency-associated peptide (LAP) [3]. This inactive TGF-β1-LAP complex forms a larger complex with latent transforming growth factor-binding proteins (LTBPs), which directly bind and release TGF-β1 from the ECM. Specifically, LTBP-4 sequesters and regulates the availability of TGF-β1 to bind with its receptor [4]. Cleavage of TGF-β1 from the latent complex is achieved through the action of proteases such as plasmin, thrombin, plasma transglutaminases, or endoglycosylases, or through the physical interaction of LAPs with other proteins [3]. Activation occurs extracellularly [3], and once TGF-β1 is released, it is able to interact with and complex its type I (usually TβR-II) and type II (usually activin receptor-like kinase (ALK) 5) receptors. The constitutively active type II receptor phosphorylates and activates the type I receptor, which in turn directly phosphorylates Smad2 and/or Smad3 (which are recruited by adaptor proteins) to initiate signal transduction through the canonical cascades [5]. Once R-Smad has been phosphorylated, it forms a complex with the common mediator Smad (co-Smad), Smad4, which translocates to the nucleus, where it directly binds defined elements on the DNA [2]. Adding to the regulation are the inhibitory Smads 6 and 7. Smad7 is involved in both branches and competes with R-Smads for interaction with the type I receptor, whereas Smad6 only participates in the BMP pathway and competes with Smad4 for binding to Smad1 [5] (Figure 1).

Figure 1

Crosstalk between the canonical and non-canonical transforming growth factor-beta1 (TGF-β1) and myostatin pathways. Once the TGF-β1 or myostatin ligands bind to the appropriate type I and type II receptors, cross-phosphorylation of the type I receptor occurs, leading to the phosphorylation of downstream effectors. In the canonical pathway, the type I receptor phosphorylates Smad2/3, which then binds to Smad4 and translocates into the nucleus to act as transcription factors. In the non-canonical pathway, the type I receptor phosphorylates proteins that are involved in the activation of the mitogen-activated protein kinases (MAPKs). Activated MAPKs can then regulate transcription factors and/or the Smad proteins through direct interactions or via downstream proteins.

TGF-β1 can also signal via induction of non-canonical pathways including MAPK. The MAPK family consists of isoforms of extracellular signal-regulated kinases (ERKs) (1 and 2), c-Jun N-terminal kinase (JNKs) (1to 3), and p38 (α, β, γ and δ). The mechanisms of MAPK activation by TGF-β1 and the subsequent biological consequences are cell-type-specific [6]. Generally in the non-Smad pathway, the type I receptor associates with the adaptor proteins, Shc and tumor necrosis factor receptor-associated factor (TRAF) 6, for the activation of Ras and TGF-β-activated kinase (TAK) 1 and subsequently, the ERK and p38/JNK pathways, respectively [7]. However, MAPK may also modulate TGF-β1-induced Smad signals and phosphorylate Smad proteins independent of TGF-β1, providing evidence for crosstalk between canonical and non-canonical TGF-β pathways [6,7] (Figure 1).

Myostatin (MSTN), predominantly expressed in skeletal muscle, also signals through the TGF-β branch [8]. It is synthesized as a precursor protein that undergoes processing by furin proteases to generate a propeptide. After proteolytic processing, however, the biologically active MSTN remains bound non-covalently to the propeptide, and in this complex, the propeptide maintains its inactive, latent state [9,10]. MSTN also seems to be regulated extracellularly by other binding proteins: follistatin [9,11], follistatin-related gene (FLRG) protein [12], and growth and differentiation factor-associated serum protein (GASP) 1 [13]. When not bound to its propeptide or binding proteins, active MSTN is able to signal to target cells by binding to the activin type II receptors, ActRIIA or ActRIIB [14,15]. The activation of the type I receptor (usually ALK5 and to a lesser extent ALK4) leads to the phosphorylation of R-Smads 2 and 3 [15]. More recently, it has been shown that MSTN is also able to induce the activation of the MAPK signaling pathway in Smad-dependent and -independent mechanisms [16-18], and to inhibit the Akt/TORC1/p70S6K signaling pathway [19] (Figure 1). For a more extensive summary of MSTN, see [20].

Physiological role of TGF-β signaling in skeletal muscle

TGF-β1 is expressed during myogenesis, and its spatial and temporal expression in the developing connective tissue is correlated with the fiber-type composition of the surrounding myotubes. Myotubes formed before the expression of TGF-β1 develop into slow fibers, whereas fast fibers form when myoblasts are adjacent to connective tissue expressing TGF-β1 [21]. TGF-β1 has been shown to inhibit the differentiation of fetal myoblasts but does not affect embryonic myoblasts [22]. In mature adult muscle, TGF-β negatively affects skeletal muscle regeneration by inhibiting satellite cell proliferation, myofiber fusion, and expression of some muscle-specific genes [23]. Furthermore, TGF-β1 induces the transformation of myogenic cells into fibrotic cells after injury [24].

Not much is known about the role of the different MAPKs in embryogenesis [25]; although, they have been shown to play a role in myogenesis and regeneration. p38 is speculated to regulate regeneration through the activation of p21, a cyclin-dependent inhibitor that causes irreversible withdrawal from the cell cycle (necessary for the differentiation of myoblasts) and through interactions with Pax7, myogenic regulatory factors, and myocyte enhancer factors [26,27]. JNK is proposed to inhibit myogenesis [28], and ERK may have multiple roles: preventing the initiation of myogenesis [29], enhancing myoblast proliferation during the acute stages, and repressing muscle-specific gene expression and myoblast differentiation, if expression is sustained [30]. Generally, in mature muscle, MAPKs mediate the transduction of diverse external stress stimuli into intracellular signals that regulate adaptive cellular responses such as proliferation, differentiation, self-renewal, and survival in diseased and healthy states [2,31]. For example, MAPK levels are modulated during exercise and aging as a stress response [31,32].

Myostatin is expressed in developing skeletal muscle throughout embryogenesis and has been shown to be a negative regulator of adult skeletal muscle mass by acting on different mechanisms [20]. Genetic studies in mice, cattle, sheep, dogs, chickens, and humans have all shown that myostatin normally functions to limit muscle mass [33-40]. In mice, targeted ablation of the Mstn gene causes a doubling of skeletal muscle mass throughout the body, as a result of a combination of muscle fiber hyperplasia and hypertrophy [33]. Moreover, postnatal inhibition of myostatin signaling through the delivery of propeptides, neutralizing antibodies, antisense RNA, inhibitory proteins, and soluble ActRIIB has been shown to induce significant muscle growth when administered to mice of different ages, demonstrating the importance of this signaling pathway in regulating muscle homeostasis [10,14,41-50].

TGF-β signaling and skeletal-muscle repair

After skeletal muscle injury, a well-coordinated repair process occurs. This process includes the release of growth factors and cytokines and the migration and proliferation of macrophages and fibroblasts that increase the production of ECM components; these components are degraded as normal regeneration occurs. The inflammatory response serves to clear myofiber debris and modulate regeneration. The formation of new myofibers begins with the activation of satellite cells, followed by proliferation, differentiation, and fusion of myocytes [51] (Figure 2).

Figure 2

Regulated and dysregulated muscle regeneration. In regulated muscle regeneration, a transient inflammatory response occurs upon injury, which includes the chemotaxis of growth factors, cytokines, macrophages, and fibroblasts. This is followed by the activation and proliferation of satellite cells. Once activated, myoblasts differentiate into myocytes, and then fuse together to form myofibers, which exhibit central nuclei. This process is primarily orchestrated by the expression of the myogenic regulatory factors. In dysregulated muscle regeneration, there is a persistent inflammatory response and overexpression of proteins such as transforming growth factor-beta1 (TGF-β1) and myostatin, which promote the formation of fibrotic tissue to replace damaged myofibers.

TGF-β1, a potent regulator of tissue wound healing and fibrosis, is physiologically upregulated in regenerating skeletal muscle after injury and exercise and is thought to participate in a transient inflammatory response to muscle damage [51,52]. Persistent exposure to the inflammatory response leads to an altered ECM and increased levels of growth factors and cytokines, including TGF-β1, which contribute to the formation of fibrotic tissue [51,52]. Therefore, TGF-β1 is one of the major factors promoting the transformation of myoblasts into fibrotic tissue after injury. Furthermore, increased levels of TGF-β1 inhibit satellite cell activation and impair myocyte differentiation [23,53] (Figure 2). Interestingly, reducing the levels of TGF-β1 in various physiological and pathological conditions associated with muscle homeostasis and regeneration has proven to be beneficial for several myopathic conditions [54-70] (Table 1).

Table 1

Comprehensive overview of studies using agents to blunt transforming growth factor (TGF)-β signaling

FDA-approved medicationsAnti-fibrotic agentsTGF-β neutralizing antibodyTGF-β receptor kinase inhibitor

Compound	Mechanism of action	Clinical condition	Model organism	Phenotypic findings	Ref

Losartan	AT1^areceptor antagonist (mostly used for hypertension, cardiomyopathies)	MFS^b	Fbn^1C1039G/+mice	Improved muscle architecture, function and regeneration	[54]

		DMD^c	mdx mice	Improved skeletal, diaphragmatic and cardiac muscle architecture, function and regeneration	[54,55]

		Muscle Injury	Young^emice	Decreased fibrosis and improved regeneration	[56]

Suramin	TGF-β1 receptor antagonist (anti-parasitic, anti-neoplasic)	DMD	mdx mice	Decreased fibrosis and prevented decrease in grip strength	[57]

		Muscle injury	Adult^fmice	Decreased fibrosis, improved regeneration and function	[58-60]


Decorin	Binds to TGF-β1 ligands	Muscle injury	Young mice	Decreased fibrosis, improved regeneration and functional recovery	[61]

		DMD	mdx mice	Decreased collagen type I levels in diaphragm	[62]

γ-Interferon	Induces Smad7 expression	Muscle injury	Young mice	Decreased fibrosis, improved regeneration and functional recovery	[63]

Pirfenidone	TGF-β1 antagonist	DMD	mdx mice	Improved cardiac function, minor alterations on the development of fibrosis, and no improvement in diaphragmatic function	[64,65]

Halofuginone	Inhibits TGF-β-dependent phosphorylation of Smad3	DMD	mdx mice	Decreased fibrosis and improved function of the heart,diaphragm and limb muscles	[66,67]

		CMD^d	dy^2J/dy^2J	Decreased fibrosis and improved functional performance but did not improve strength	[68]


Neutralizes TGF-β (1 and/or 2) ligands		MFS	Fbn^1C1039G/+mice	Prevented muscle atrophy and improved regeneration	[54]

		DMD	mdx mice	Decreased fibrosis and improved regeneration	[54,69]

		Sarcopenia	Aged^gmice	Failed to improve regeneration	[70]


Decoy receptor composed of extracellular portion of TGF-β receptor II		Sarcopenia	Aged mice	Improved regeneration after direct intramuscular injection	[70]

^aAngiotensin II type 1 receptor.

^bMarfan syndrome.

^cDuchenne muscular dystrophy.

^dCongenital muscular dystrophy.

^eAge ≤ 3 months.

^fAge 3-15 months.

^gAge ≥ 15 months.

Myostatin also impairs skeletal muscle regeneration. It is proposed to hinder the chemotaxis of macrophages and myoblasts [71], while simultaneously activating and attracting fibroblasts to the site of injury. Once fibroblasts are within the environment of the injured muscle, they express MSTN and differentiate into myofibroblasts, a process that in turn accelerates the deposition of collagen and connective tissue, ultimately promoting the formation of tissue fibrosis [72,73]. Furthermore, myostatin inhibits the activation, differentiation, and self-renewal of satellite cells [71,74,75] and the expression of the muscle regulatory factors crucial for the regeneration and differentiation process of myofibers [76,77] (Figure 2). Inhibiting MSTN in various myopathic conditions has yielded mixed results, depending on the disease model and mechanism of inhibition [43,44,48,50,78-100] (Table 2).

Table 2

Comprehensive overview of studies using post-natal inhibition of myostatin

Neutralizing antibody: binds to active myostatin and prevents receptor bindingMSTN Propeptide: binds to myostatin and prevents release of active formFollistatin: inhibitory protein that binds to myostatinHDAC Inhibitors: induce expression of follistatinMSTN peptide: dominant negative truncated myostatin peptide that binds ActRIIBAntisense RNA: binds myostatin messenger RNA and inactivates it

Disease	Model organism	Phenotypic findings	Ref

DMD^a	mdx mice	Improved regeneration and function, induced hypertrophy, decreased degeneration (diaphragm) and fibrosis	[78,79]

LGMD2C^b	sgcg^-/-mice	Improved function, induced hypertrophy but no histopathological improvement	[80]

LGMD2F	sgcd^-/-mice	Increased muscle mass, regeneration (young) and fibrosis (aged)	[81]

ALS^c	SOD1^G93A mice and rats	Delayed onset of muscle atrophy and functional decline without extending survival	[82]

Sarcopenia	Aged^fmice	Prevented loss of body weight, muscle mass and function, and decline in physical activity, reduced apoptosis, no change in fibrosis	[44,83]

Disuse atrophy	Adult^gmice	Partially protected against but did not prevent atrophy	[99]

ActRIIB-Fc^d: soluble, decoy receptor binding active myostatin

DMD	mdx mice	Increased body weight and function, induced hypertrophy	[84,100]

LGMD1C	CAV-3^P104Lmice	Induced muscle hypertrophy	[85]

SMA^e	SMAΔ7 mice	Modestly increased muscle weight and strength, decreased survival	[86]

ALS	SOD1^G93Amice	Delayed onset of disease but did not extend survival, reduced weakness after onset	[87]

Cachexia	Lewis-lung carcinoma	Protected against loss of body weight and muscle mass	[88]

Cachexia	Colon-26 carcinoma	Protected against or restored loss of body weight, muscle mass and grip strength, and increased survival	[88,89]


DMD	mdx mice	Induced hypertrophy, increased strength, improved histopathological features of limb and diaphragm, decreased endurance, produced adverse effects on cardiomyopathy	[48,50,90]

LGMD2A	Capn3^-/-mice	Increased muscle mass and force, no improvement in histopathological features	[91]

LGMD2D	sgca^-/-mice	Insufficient delivery of vector resulted in no hypertrophy or any change in necrosis	[91]

Muscle Injury	Adult mice	Increased muscle mass, improved regeneration, decreased fibrosis	[92]


SMA	SMAΔ7 mice	Improved muscle mass (during early stages of disease), motor function and extended survival	[93]

ALS	SOD1^G93Amice	Increased muscle mass (hyperplasia) and strength (not performance) but no survival extension	[94]


DMD	mdx mice	Induced hypertrophy, decreased fibrosis and necrosis, restored muscle architecture, increased strength and performance	[95]

LGMD2D	sgca^-/-mice	Induced hypertrophy and reduced fibrosis	[95]

Cachexia	Colon-26 carcinoma	Did not protect against loss of body weight, muscle mass or function	[88,96]

Muscle injury	Young^hmice	Improved regeneration	[97]


Sarcopenia	Aged mice	Improved grip strength and enhanced inflammatory response after injury	[98]

Muscle injury	Adult mice	Improved regeneration, decrease in necrosis	[98]


Cachexia	S-180 ascitic tumor	Increased muscle mass	[43]

^aDuchenne muscular dystrophy.

^bLimb-girdle muscular dystrophy.

^cAmyotrophic lateral sclerosis.

^dActivin type IIB receptor.

^eSpinal muscular atrophy.

^fAge≥ 15 months.

^gAge 3-15 months.

^hAge ≤ 3 months.

Role of TGF-β signaling in disease pathogenesis of inherited myopathies

Dysregulation of TGF-β signaling has been implicated in various pathological conditions affecting skeletal muscle, both inherited and acquired [51]. Inherited conditions can be progressive, and therefore, there are unique phenotypic characteristics that may require different modes of intervention. Indeed, increased levels of TGF-β, MAPK, and/or MSTN have been associated with spinal muscular atrophy and Kennedy disease [101,102], and inhibition of MSTN improves familial amyotrophic lateral sclerosis (ALS) [82,87], but this review focuses on altered signaling in the pathogenesis of Marfan syndrome (MFS) and the muscular dystrophies.

MFS is an autosomal dominant systemic disorder of connective tissue, caused by mutations in FBN1, the gene encoding the ECM protein, fibrillin-1 [103]. A large subset of patients exhibit a significant decrease in muscle mass, often associated with hypotonia, particularly during early childhood, and experience a life-long inability to increase muscle mass despite physical exercise. Histological analyses of skeletal muscle from fibrillin-1-deficient mice and patients with MFS demonstrated a decrease in the number and size of myofibers, accompanied by an increase in fibrosis, fat deposition, and the number of split fibers. Further molecular analyses revealed that an increase in TGF-β signaling was indeed responsible for the abnormal muscle phenotype and the impaired ability to regenerate muscle in response to injury. Interestingly, when TGF-β signaling was blunted via treatment with a TGF-β neutralizing antibody or losartan, mice deficient in fibrillin-1 exhibited normal muscle architecture and regeneration capabilities [54].

'Muscular dystrophy' (MD) is a term used to describe a group of over 30 inherited disorders characterized by variable progressive muscle weakness and wasting [104,105]. Genetic mutations in genes encoding proteins spanning every subcellular aspect of the myofiber have been described [105]. There are currently no unifying hypotheses integrating all forms of MDs, but various lines of evidence suggest that repeated cycles of degeneration and regeneration may eventually impair the ability of satellite cells to repopulate damaged muscle [104]. Once muscle regeneration declines, there is often an accumulation of inflammation and fibrosis, which results in an abundance of growth factors and cytokines including TGF-β1, as stated above [51,62,106-108]. Similarly, the levels of decorin and biglycan, components of the ECM that interact with cytokines such as TGF-β1, as well as modulations of MAPK and myostatin signaling, are altered in various forms of muscular dystrophies including congenital MD, Emery-Dreifuss MD (EDMD) and Becker MD [109-115]. This review will elaborate on findings in Duchenne and limb-girdle MDs.

Duchenne muscular dystrophy (DMD) is an X-linked disorder characterized by a complete lack of dystrophin, which renders the myofiber membrane unstable. Inflammation is thought to precede the overexpression of TGF-β1 and actual muscle wasting [116,117]. Additionally, other factors including ECM components, immune system components, osteopontin, and fibrinogen are increased and have been linked to fibrosis in patients and animal models of DMD [52,108-110,116,118-120]. Furthermore, increased levels of the MAPKs ERK1/2, JNK1, and p38 have also been suggested to play a role in the pathogenesis of the skeletal and cardiac muscle phenotype in animal models of DMD [121-123]. Insight into the different factors contributing to the fibrosis accompanying DMD has led to various mechanisms to improve the phenotype observed in cardiac and skeletal (diaphragm and limb) muscles (Table 1 and 2) [52,54,64,124,125].

Limb-girdle muscular dystrophy (LGMD) describes a group of disorders primarily affecting the shoulder and pelvic girdle muscles, which have both autosomal dominant and recessive inheritance, and involve a variety of proteins including sarcoglycans, dysferlin, and caveolin [105]. Studies in a Drosophila model of LGMD with γ/δ-sarcoglycan deficiency have shown that partial reduction of the Drosophila genes homologous to Smads 2/3, Smads 1/5/7, and Smad4 improved muscle function, as shown by increased climbing ability of the flies. Similarly, reducing the levels of the homologue for Smads 2/3 and Smad4 improved the heart tube phenotype [125]. Not only has this research provided a novel animal model for studying dystrophic disease processes, but the results also indicate that targeting the R-Smads and co-Smad may be of therapeutic interest. Furthermore, genetic manipulation of LTBP-4, a latent TGF-β binding protein discussed above, affected the severity of a mouse model of sarcoglycan-deficient LGMD2C, providing evidence for an important genetic modifier of MD. An insertion in the LTBP4 gene reduced proteolysis and Smad signaling [4]. Thus, targeting the latent complex of TGF-β1 opens up yet another therapeutic avenue for inhibiting this cytokine in various conditions affecting skeletal muscle.

Acquired myopathies implicating aberrant TGF-β signaling in disease progression

Alterations in the expression of the TGF-β signaling cascades have also been linked to acquired forms of myopathies. Muscle atrophy caused by hypoxia [126], microgravity exposure [127], starvation [128], acute daily psychological stress [129], various models of disuse [130-137], cancer [138,139], sporadic ALS [140], HIV [141], and glucocorticoid steroids [142] is associated with increased activation of MAPK, TGF-β1, and/or MSTN. However, in this paper, we focus on sarcopenia and critical illness myopathy (CIM).

Sarcopenia refers to the physiological age-related loss of skeletal muscle mass and function [143]. Several changes occur with age, including a decrease in myofiber size and number and diminished ability of satellite cells to activate and proliferate in response to injury, leading to impaired muscle remodeling [144,145]. The molecular mechanisms underlying sarcopenia are largely unknown. However, alterations in the canonical and non-canonical TGF-β signaling pathways have been shown to play a role in the pathogenesis of sarcopenia. Studies in elderly men have demonstrated an increase in MAPK at baseline, suggesting that aging skeletal muscle is functioning under 'stress-like' conditions at rest [32]. However, a different study conducted in mice and humans found an age-related decrease in ERK signaling in skeletal muscle and satellite cells, suggesting a contribution to the impaired regeneration [146]. Clearly, more in-depth studies are necessary to characterize the role of MAPK signaling in aging. Additionally, alterations in the canonical TGF-β pathway include an increase in circulating TGF-β1 levels and pSmad3, which contributes to the enrichment of connective tissue within the ECM, creating an environment that interferes with satellite cell activation and proliferation and subsequent remodeling [70,145]. Other studies have shown an upregulation of MSTN [147] and that inhibition of MSTN results in an increase in muscle mass, function, and regeneration in sarcopenic mice, suggesting an important role for this protein in the process of age-related loss of muscle mass [44,98] (Table 2).

CIM is characterized by generalized progressive muscle weakness and atrophy, occurring in critically ill patients who are hospitalized in the intensive care unit [148,149]. There are several factors thought to contribute to the loss of muscle mass in CIM, including immobilization, systemic inflammation, high dose steroids, and other toxins [148]. The precise molecular mechanisms underlying CIM are unknown [148]; however, constitutively active members of the canonical and non-canonical TGF-β signaling pathways may contribute to the muscle phenotype. In fact, atrophic fibers with apoptotic features express TGF-β ligands and receptors, p38, and downstream effectors of pJNK [149]. It is therefore tempting to speculate that TGF-β inhibition may slow or halt the progression of CIM.

Therapeutic inhibition of TGF-β signaling

Aberrant TGF-β signaling has an important role in inherited and acquired myopathies. Therefore, research has been aimed at identifying compounds that can attenuate the increased signaling of TGF-β1, MSTN, and/or MAPK levels in order to improve disease phenotypes.

Several compounds have been shown to reduce the levels of TGF-β1 in myopathies. These include FDA-approved medications with other primary clinical uses, anti-fibrotic agents, TGF-β neutralizing antibodies, and TGF-β receptor blockers. Most yielded favorable results, but there are some conditions in which blunting TGF-β signaling was not beneficial. Table 1 provides a comprehensive overview of existing agents targeting TGF-β signaling in specific disease models.

Losartan is a widely studied, FDA-approved drug commonly used in the treatment of hypertension. Its ability to attenuate TGF-β signaling in chronic renal disease, cardiomyopathies, and MFS [54,150,151] made it an appealing molecule in the treatment of myopathies associated with increased TGF-β signaling. Long-term administration of losartan to dystrophin-negative mdx mice attenuated TGF-β signaling, decreased skeletal muscle fibrosis, and improved muscle regeneration and in vitro and in vivo function [54]. Furthermore, long-term administration of losartan, in conjunction with exercise, in mdx mice improved the cardiac muscle function and decreased fibrosis in the cardiac, diaphragm, and limb muscles but did not improve limb muscle function [55]. Other mechanisms of TGF-β inhibition have also yielded favorable results in the treatment of DMD and other conditions (Table 1).

Furthermore, recent experimental evidence has identified novel therapeutic targets in the TGF-β pathway. Molecules involved upstream (LTBP-4) and downstream (R-Smads and co-Smad) have been shown to modulate disease severity [4,125]. It is important to emphasize that LTBP-4 is a specific target for TGF-β1 [4], whereas Smad molecules incorporate a variety of different pathways, which could potentially lead to a number of adverse effects if they were therapeutically modified [125,152] (Figure 1). Moreover, osteopontin, an inflammatory regulator that also modulates TGF-β1, has recently been shown to be upregulated during muscle regeneration and in DMD [118,153-155]. Lack of osteopontin in mdx mice improved fibrotic tissue formation and muscle function, making osteopontin a potential therapeutic target [118].

In addition to altering TGF-β1 signaling, a number of compounds have been shown to inhibit myostatin signaling. Numerous studies breeding myostatin-null mice to several mouse models of inherited and acquired myopathies have shown various beneficial and non-beneficial effects [81,85,88,98,156-159]. Interestingly, several studies on myostatin-null mice alone have shown that despite an increase in muscle fiber size, there is no increase in specific force, which is probably due to a disturbance in mitochondrial metabolism [160,161]. Furthermore, myostatin-null mice have also been reported to have brittle tendons, which may contribute to the decrease in specific force [162]. However, it is important to emphasize that these studies were performed in mice with a complete lack of myostatin during the development of skeletal muscle. Thus, caution is needed when extrapolating the findings obtained from myostatin-null mice to the various compounds targeting myostatin signaling postnatally.

There are several pharmacological compounds that inhibit MSTN postnatally: MSTN propeptide, MSTN peptide, inhibitory proteins (follistatin), MSTN neutralizing antibodies, histone deacetylase inhibitors, and soluble ActRIIB. These techniques have been used in various disease models, and a detailed overview is presented in Table 2.

The soluble receptor, ActRIIB, is currently being used in multiple clinical trials and has been explored in various animal models including a model of DMD. It is important to note that targeting ActRIIB could lead to adverse side effects, because its expression is not limited to skeletal muscle [84] and because other members of the TGF-β superfamily besides myostatin bind to it [14]. Furthermore, myostatin can also signal through another receptor, ActRIIA, but with lower affinity [15].

Preclinical trials with soluble ActRIIB in mdx mice have shown that short-term (3 months) intraperitoneal administration increased skeletal muscle mass and in vitro function and caused a decrease in creatine kinase levels [100]. Adeno-associated virus (AAV)-mediated gene transfer of a soluble form of the extracellular domain of the ActRIIB to the liver provided similar results after 3.5 months, but no changes to cardiac muscle mass were seen [84]. However, long-term (11 months) myostatin inhibition using a recombinant AAV to overexpress myostatin propeptide in mdx mice did not reduce the amount of fibrosis in the diaphragm, but caused cardiac hypertrophy and impaired function in a dose-dependent manner [50]. These results indicate that all modes of myostatin inhibition may not be beneficial.

Similar to TGF-β1 and MSTN, perturbations of MAPK signaling have been documented in several myopathies, but not many studies exist examining the effects of inhibition on disease progression. Some evidence suggest that a reduction in JNK and ERK signaling might be beneficial in DMD [122] and cachexia [163], respectively, but further studies are needed to elaborate on these initial findings. Furthermore, a number of studies have shown that inhibition of the MAPK pathway is beneficial for the cardiomyopathic phenotype of various muscular dystrophies. Specifically, it has been shown that blunting ERK or JNK before and after onset of EDMD results in less cardiac fibrosis and an overall improved function [164-166]. Thus, this is a potential area of interest in designing future pharmacological compounds, because of the potential benefits and current lack of FDA-approved MAPK inhibitors [166].

Conclusions

Increased activity of the TGF-β superfamily plays an important role in the pathogenesis of both inherited and acquired forms of neuromuscular disorders. These alterations cause an unfavorable environment for muscle regeneration and promote an increase in fibrotic tissue formation (Figure 2). Future studies will need to address the precise timeline of alterations in TGF-β signaling in various disease processes in order to establish the optimal therapeutic intervention. A number of drugs (Table 1; Table 2) are close to or currently in clinical trials. These and future clinical trials will need to establish the safety and efficacy of these drugs and address whether certain clinical conditions may benefit from a multi-targeted approach.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TNB designed the study and drafted the manuscript. RDC drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This project was funded by the National Institute on Aging, Claude D. Pepper Older Americans Independence Center, parent grant P30AG021334 to RDC and supplemental grant P30AG021334-08S1 to TNB. RDC is also supported by the NIH Director's New Innovator Award DP2 OD004515, by NIH 5K08NS055879 award, and MDA #101938.

References

1. GordonKJBlobeGCRole of transforming growth factor-beta superfamily signaling pathways in human diseaseBiochim Biophys Acta20081782197228[PubMed][Google Scholar]
2. GuoXWangXFSignaling cross-talk between TGF-beta/BMP and other pathwaysCell Res2009197188[PubMed][Google Scholar]
3. Barcellos-HoffMHLatency and activation in the control of TGF-betaJ Mammary Gland Biol Neoplasia19961353363[PubMed][Google Scholar]
4. HeydemannACecoELimJEHadhazyMRyderPMoranJLBeierDRPalmerAAMcNallyEMLatent TGF-beta-binding protein 4 modifies muscular dystrophy in miceJ Clin Invest200911937033712[PubMed][Google Scholar]
5. RahimiRALeofEBTGF-beta signaling: a tale of two responsesJ Cell Biochem2007102593608[PubMed][Google Scholar]
6. JavelaudDMauvielACrosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesisOncogene20052457425750[PubMed][Google Scholar]
7. ZhangYENon-Smad pathways in TGF-beta signalingCell Res200919128139[PubMed][Google Scholar]
8. MoustakasAHeldinCHNon-Smad TGF-beta signalsJ Cell Sci200511835733584[PubMed][Google Scholar]
9. ThiesRSChenTDaviesMVTomkinsonKNPearsonAAShakeyQAWolfmanNMGDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor bindingGrowth Factors200118251259[PubMed][Google Scholar]
10. WolfmanNMMcPherronACPappanoWNDaviesMVSongKTomkinsonKNWrightJFZhaoLSebaldSMGreenspanDSLeeSJActivation of latent myostatin by the BMP-1/tolloid family of metalloproteinasesProc Natl Acad Sci USA20031001584215846[PubMed][Google Scholar]
11. ZimmersTADaviesMVKoniarisLGHaynesPEsquelaAFTomkinsonKNMcPherronACWolfmanNMLeeSJInduction of cachexia in mice by systemically administered myostatinScience200229614861488[PubMed][Google Scholar]
12. HillJJDaviesMVPearsonAAWangJHHewickRMWolfmanNMQiuYThe myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serumJ Biol Chem20022774073540741[PubMed][Google Scholar]
13. HillJJQiuYHewickRMWolfmanNMRegulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domainsMol Endocrinol20031711441154[PubMed][Google Scholar]
14. LeeSJReedLADaviesMVGirgenrathSGoadMETomkinsonKNWrightJFBarkerCEhrmantrautGHolmstromJRegulation of muscle growth by multiple ligands signaling through activin type II receptorsProc Natl Acad Sci USA20051021811718122[PubMed][Google Scholar]
15. RebbapragadaABenchabaneHWranaJLCelesteAJAttisanoLMyostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesisMol Cell Biol20032372307242[PubMed][Google Scholar]
16. YangWChenYZhangYWangXYangNZhuDExtracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repressionCancer Res20066613201326[PubMed][Google Scholar]
17. HuangZChenDZhangKYuBChenXMengJRegulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cellsCell Signal20071922862295[PubMed][Google Scholar]
18. PhilipBLuZGaoYRegulation of GDF-8 signaling by the p38 MAPKCell Signal200517365375[PubMed][Google Scholar]
19. TrendelenburgAUMeyerARohnerDBoyleJHatakeyamaSGlassDJMyostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube sizeAm J Physiol Cell Physiol2009296C12581270[PubMed][Google Scholar]
20. LeeSJRegulation of muscle mass by myostatinAnnu Rev Cell Dev Biol2004206186[PubMed][Google Scholar]
21. McLennanISLocalisation of transforming growth factor beta 1 in developing muscles: implications for connective tissue and fiber type pattern formationDev Dyn1993197281290[PubMed][Google Scholar]
22. Cusella-De AngelisMGMolinariSLe DonneAColettaMVivarelliEBoucheMMolinaroMFerrariSCossuGDifferential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesisDevelopment1994120925933[PubMed][Google Scholar]
23. AllenREBoxhornLKInhibition of skeletal muscle satellite cell differentiation by transforming growth factor-betaJ Cell Physiol1987133567572[PubMed][Google Scholar]
24. LiYFosterWDeasyBMChanYPriskVTangYCumminsJHuardJTransforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesisAm J Pathol200416410071019[PubMed][Google Scholar]
25. DickinsonRJWilliamsDJSlackDNWilliamsonJSeternesOMKeyseSMCharacterization of a murine gene encoding a developmentally regulated cytoplasmic dual-specificity mitogen-activated protein kinase phosphataseBiochem J2002364145155[PubMed][Google Scholar]
26. WuZWoodringPJBhaktaKSTamuraKWenFFeramiscoJRKarinMWangJYPuriPLp38 and extracellular signal-regulated kinases regulate the myogenic program at multiple stepsMol Cell Biol20002039513964[PubMed][Google Scholar]
27. PalaciosDMozzettaCConsalviSCarettiGSacconeVProserpioVMarquezVEValenteSMaiAForcalesSVTNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regenerationCell Stem Cell20107455469[PubMed][Google Scholar]
28. MerianeMRouxPPrimigMFortPGauthier-RouviereCCritical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathwaysMol Biol Cell20001125132528[PubMed][Google Scholar]
29. BennettAMTonksNKRegulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinasesScience199727812881291[PubMed][Google Scholar]
30. JonesNCFedorovYVRosenthalRSOlwinBBERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusionJ Cell Physiol2001186104115[PubMed][Google Scholar]
31. WidegrenUJiangXJKrookAChibalinAVBjornholmMTallyMRothRAHenrikssonJWallberg-henrikssonHZierathJRDivergent effects of exercise on metabolic and mitogenic signaling pathways in human skeletal muscleFASEB J19981213791389[PubMed][Google Scholar]
32. WilliamsonDGallagherPHarberMHollonCTrappeSMitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscleJ Physiol2003547977987[PubMed][Google Scholar]
33. McPherronACLawlerAMLeeSJRegulation of skeletal muscle mass in mice by a new TGF-beta superfamily memberNature19973878390[PubMed][Google Scholar]
34. SchuelkeMWagnerKRStolzLEHubnerCRiebelTKomenWBraunTTobinJFLeeSJMyostatin mutation associated with gross muscle hypertrophy in a childN Engl J Med200435026822688[PubMed][Google Scholar]
35. GrobetLMartinLJPonceletDPirottinDBrouwersBRiquetJSchoeberleinADunnerSMenissierFMassabandaJA deletion in the bovine myostatin gene causes the double-muscled phenotype in cattleNat Genet1997177174[PubMed][Google Scholar]
36. KambadurRSharmaMSmithTPBassJJMutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattleGenome Res19977910916[PubMed][Google Scholar]
37. ZhiliangGDahaiZNingLHuiLXuemeiDChangxinWThe single nucleotide polymorphisms of the chicken myostatin gene are associated with skeletal muscle and adipose growthSci China C Life Sci2004472530[PubMed][Google Scholar]
38. SheltonGDEngvallEGross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin geneNeuromuscul Disord200717721722[PubMed][Google Scholar]
39. MosherDSQuignonPBustamanteCDSutterNBMellershCSParkerHGOstranderEAA mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogsPLoS Genet20073e79[PubMed][Google Scholar]
40. ClopAMarcqFTakedaHPirottinDTordoirXBibeBBouixJCaimentFElsenJMEychenneFA mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheepNat Genet200638813818[PubMed][Google Scholar]
41. WhittemoreLASongKLiXAghajanianJDaviesMGirgenrathSHillJJJalenakMKelleyPKnightAInhibition of myostatin in adult mice increases skeletal muscle mass and strengthBiochem Biophys Res Commun2003300965971[PubMed][Google Scholar]
42. HaidetAMRizoLHandyCUmapathiPEagleAShillingCBoueDMartinPTSahenkZMendellJRKasparBKLong-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProc Natl Acad Sci USA200810543184322[PubMed][Google Scholar]
43. LiuCMYangZLiuCWWangRTienPDaleRSunLQMyostatin antisense RNA-mediated muscle growth in normal and cancer cachexia miceGene Ther200815155160[PubMed][Google Scholar]
44. MurphyKTKoopmanRNaimTLegerBTrieuJIbebunjoCLynchGSAntibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and functionFASEB J20102444334442[PubMed][Google Scholar]
45. LiZZhaoBKimYSHuCYYangJAdministration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growthMol Reprod Dev2010777682[PubMed][Google Scholar]
46. CadenaSMTomkinsonKNMonnellTESpaitsMSKumarRUnderwoodKWPearsallRSLacheyJLAdministration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber typeJ Appl Physiol2010109635642[PubMed][Google Scholar]
47. MatsakasAFosterKOttoAMachariaRElashryMIFeistSGrahamIFosterHYaworskyPWalshFMolecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult miceNeuromuscul Disord200919489499[PubMed][Google Scholar]
48. QiaoCLiJJiangJZhuXWangBXiaoXMyostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx miceHum Gene Ther200819241254[PubMed][Google Scholar]
49. HuSChenCShengJSunYCaoXQiaoJEnhanced muscle growth by plasmid-mediated delivery of myostatin propeptideJ Biomed Biotechnol20102010862591[PubMed][Google Scholar]
50. MorineKJBishLTPendrakKSleeperMMBartonERSweeneyHLSystemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic micePLoS One20105e9176[PubMed][Google Scholar]
51. SerranoALMunoz-CanovesPRegulation and dysregulation of fibrosis in skeletal muscleExp Cell Res201031630503058[PubMed][Google Scholar]
52. GosselinLEMcCormickKMTargeting the immune system to improve ventilatory function in muscular dystrophyMed Sci Sports Exerc2004364451[PubMed][Google Scholar]
53. AllenREBoxhornLKRegulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factorJ Cell Physiol1989138311315[PubMed][Google Scholar]
54. CohnRDvan ErpCHabashiJPSoleimaniAAKleinECLisiMTGamradtMap RhysCMHolmTMLoeysBLAngiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic statesNat Med200713204210[PubMed][Google Scholar]
55. SpurneyCFSaliAGuerronADIantornoMYuQGordish-DressmanHRayavarapuSvan der MeulenJHoffmanEPNagarajuKLosartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx miceJ Cardiovasc Pharmacol Ther2011168795[PubMed][Google Scholar]
56. BedairHSKarthikeyanTQuinteroALiYHuardJAngiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscleAm J Sports Med20083615481554[PubMed][Google Scholar]
57. TanigutiAPPertilleAMatsumuraCYSanto NetoHMarquesMJPrevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blockerMuscle Nerve2011438287[PubMed][Google Scholar]
58. NozakiMLiYZhuJAmbrosioFUeharaKFuFHHuardJImproved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growthAm J Sports Med20083623542362[PubMed][Google Scholar]
59. ChanYSLiYFosterWHoraguchiTSomogyiGFuFHHuardJAntifibrotic effects of suramin in injured skeletal muscle after lacerationJ Appl Physiol200395771780[PubMed][Google Scholar]
60. ChanYSLiYFosterWFuFHHuardJThe use of suramin, an antifibrotic agent, to improve muscle recovery after strain injuryAm J Sports Med2005334351[PubMed][Google Scholar]
61. FukushimaKBadlaniNUsasARianoFFuFHuardJThe use of an antifibrosis agent to improve muscle recovery after lacerationAm J Sports Med200129394402[PubMed][Google Scholar]
62. GosselinLEWilliamsJEDeeringMBrazeauDKourySMartinezDALocalization and early time course of TGF-beta 1 mRNA expression in dystrophic muscleMuscle Nerve200430645653[PubMed][Google Scholar]
63. FosterWLiYUsasASomogyiGHuardJGamma interferon as an antifibrosis agent in skeletal muscleJ Orthop Res200321798804[PubMed][Google Scholar]
64. Van ErpCIrwinNGHoeyAJLong-term administration of pirfenidone improves cardiac function in mdx miceMuscle Nerve200634327334[PubMed][Google Scholar]
65. GosselinLEWilliamsJEPersoniusKFarkasGAA comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidoneMuscle Nerve200735208216[PubMed][Google Scholar]
66. TurgemanTHagaiYHuebnerKJassalDSAndersonJEGeninONaglerAHalevyOPinesMPrevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginoneNeuromuscul Disord200818857868[PubMed][Google Scholar]
67. HuebnerKDJassalDSHalevyOPinesMAndersonJEFunctional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginoneAm J Physiol Heart Circ Physiol2008294H15501561[PubMed][Google Scholar]
68. NevoYHalevyOGeninOMosheITurgemanTHarelMBitonEReifSPinesMFibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient miceMuscle Nerve201042218229[PubMed][Google Scholar]
69. AndreettaFBernasconiPBaggiFFerroPOlivaLArnoldiECornelioFMantegazzaRConfalonieriPImmunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapyJ Neuroimmunol20061757786[PubMed][Google Scholar]
70. CarlsonMEConboyMJHsuMBarchasLJeongJAgrawalAMikelsAJAgrawalSSchafferDVConboyIMRelative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responsesAging Cell20098676689[PubMed][Google Scholar]
71. McCroskerySThomasMPlattLHennebryANishimuraTMcLeayLSharmaMKambadurRImproved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null miceJ Cell Sci200511835313541[PubMed][Google Scholar]
72. ZhuJLiYShenWQiaoCAmbrosioFLavasaniMNozakiMBrancaMFHuardJRelationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosisJ Biol Chem20072822585225863[PubMed][Google Scholar]
73. LiZBKolliasHDWagnerKRMyostatin directly regulates skeletal muscle fibrosisJ Biol Chem20082831937119378[PubMed][Google Scholar]
74. McCroskerySThomasMMaxwellLSharmaMKambadurRMyostatin negatively regulates satellite cell activation and self-renewalJ Cell Biol200316211351147[PubMed][Google Scholar]
75. CarnacGVernusBBonnieuAMyostatin in the pathophysiology of skeletal muscleCurr Genomics20078415422[PubMed][Google Scholar]
76. LangleyBThomasMBishopASharmaMGilmourSKambadurRMyostatin inhibits myoblast differentiation by down-regulating MyoD expressionJ Biol Chem20022774983149840[PubMed][Google Scholar]
77. JouliaDBernardiHGarandelVRabenoelinaFVernusBCabelloGMechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatinExp Cell Res2003286263275[PubMed][Google Scholar]
78. BogdanovichSKragTOBartonERMorrisLDWhittemoreLAAhimaRSKhuranaTSFunctional improvement of dystrophic muscle by myostatin blockadeNature2002420418421[PubMed][Google Scholar]
79. MurphyKTRyallJGSnellSMNairLKoopmanRKrasneyPAIbebunjoCHoldenKSLoriaPMSalattoCTLynchGSAntibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx miceAm J Pathol201017624252434[PubMed][Google Scholar]
80. BogdanovichSMcNallyEMKhuranaTSMyostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2CMuscle Nerve200837308316[PubMed][Google Scholar]
81. ParsonsSAMillayDPSargentMAMcNallyEMMolkentinJDAge-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophyAm J Pathol200616819751985[PubMed][Google Scholar]
82. HolzbaurELHowlandDSWeberNWallaceKSheYKwakSTchistiakovaLAMurphyEHinsonJKarimRMyostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosisNeurobiol Dis200623697707[PubMed][Google Scholar]
83. LeBrasseurNKSchelhornTMBernardoBLCosgrovePGLoriaPMBrownTAMyostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged miceJ Gerontol A Biol Sci Med Sci200964940948[PubMed][Google Scholar]
84. MorineKJBishLTSelsbyJTGazzaraJAPendrakKSleeperMMBartonERLeeSJSweeneyHLActivin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophyMuscle Nerve201042722730[PubMed][Google Scholar]
85. OhsawaYHagiwaraHNakataniMYasueAMoriyamaKMurakamiTTsuchidaKNojiSSunadaYMuscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibitionJ Clin Invest200611629242934[PubMed][Google Scholar]
86. SumnerCJWeeCDWarsingLCChoeDWNgASLutzCWagnerKRInhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy miceHum Mol Genet20091831453152[PubMed][Google Scholar]
87. MorrisonBMLacheyJLWarsingLCTingBLPullenAEUnderwoodKWKumarRSakoDGrinbergAWongVA soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosisExp Neurol2009217258268[PubMed][Google Scholar]
88. Benny KlimekMEAydogduTLinkMJPonsMKoniarisLGZimmersTAAcute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexiaBiochem Biophys Res Commun201039115481554[PubMed][Google Scholar]
89. ZhouXWangJLLuJSongYKwakKSJiaoQRosenfeldRChenQBooneTSimonetWSReversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survivalCell2010142531543[PubMed][Google Scholar]
90. BogdanovichSPerkinsKJKragTOWhittemoreLAKhuranaTSMyostatin propeptide-mediated amelioration of dystrophic pathophysiologyFASEB J200519543549[PubMed][Google Scholar]
91. BartoliMPoupiotJVulinAFougerousseFArandelLDanieleNRoudautCNouletFGarciaLDanosORichardIAAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiencyGene Ther200714733740[PubMed][Google Scholar]
92. HamrickMWArounleutPKellumECainMImmelDLiangLFRecombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injuryJ Trauma201069579583[PubMed][Google Scholar]
93. RoseFFJrMattisVBRindtHLorsonCLDelivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophyHum Mol Genet2009189971005[PubMed][Google Scholar]
94. MillerTMKimSHYamanakaKHesterMUmapathiPArnsonHRizoLMendellJRGageFHClevelandDWKasparBKGene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosisProc Natl Acad Sci USA20061031954619551[PubMed][Google Scholar]
95. MinettiGCColussiCAdamiRSerraCMozzettaCParenteVFortuniSStrainoSSampaolesiMDi PadovaMFunctional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitorsNat Med20061211471150[PubMed][Google Scholar]
96. BonettoAPennaFMineroVGReffoPBonelliGBaccinoFMCostelliPDeacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing miceCurr Cancer Drug Targets20099608616[PubMed][Google Scholar]
97. IezziSDi PadovaMSerraCCarettiGSimoneCMaklanEMinettiGZhaoPHoffmanEPPuriPLSartorelliVDeacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatinDev Cell20046673684[PubMed][Google Scholar]
98. SiriettVPlattLSalernoMSLingNKambadurRSharmaMProlonged absence of myostatin reduces sarcopeniaJ Cell Physiol2006209866873[PubMed][Google Scholar]
99. MurphyKTCobaniVRyallJGIbebunjoCLynchGSAcute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in miceJ Appl Physiol2011[Google Scholar]
100. PistilliEEBogdanovichSGoncalvesMDAhimaRSLacheyJSeehraJKhuranaTTargeting the activin type IIB Receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophyAm J Pathol201117812871297[PubMed][Google Scholar]
101. MillinoCFaninMVettoriALavederPMostacciuoloMLAngeliniCLanfranchiGDifferent atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophyBMC Med2009714[PubMed][Google Scholar]
102. KatsunoMAdachiHMinamiyamaMWazaMDoiHKondoNMizoguchiHNittaAYamadaKBannoHDisrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophyJ Neurosci20103057025712[PubMed][Google Scholar]
103. DietzHCCuttingGRPyeritzREMaslenCLSakaiLYCorsonGMPuffenbergerEGHamoshANanthakumarEJCurristinSMMarfan syndrome caused by a recurrent de novo missense mutation in the fibrillin geneNature1991352337339[PubMed][Google Scholar]
104. MorganJEZammitPSDirect effects of the pathogenic mutation on satellite cell function in muscular dystrophyExp Cell Res201031631003108[PubMed][Google Scholar]
105. CohnRDCampbellKPMolecular basis of muscular dystrophiesMuscle Nerve20002314561471[PubMed][Google Scholar]
106. BernasconiPDi BlasiCMoraMMorandiLGalbiatiSConfalonieriPCornelioFMantegazzaRTransforming growth factor-beta1 and fibrosis in congenital muscular dystrophiesNeuromuscul Disord199992833[PubMed][Google Scholar]
107. IshitobiMHaginoyaKZhaoYOhnumaAMinatoJYanagisawaTTanabuMKikuchiMIinumaKElevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophyNeuroreport20001140334035[PubMed][Google Scholar]
108. PasseriniLBernasconiPBaggiFConfalonieriPCozziFCornelioFMantegazzaRFibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophyNeuromuscul Disord200212828835[PubMed][Google Scholar]
109. ZanottiSNegriTCappellettiCBernasconiPCanioniEDi BlasiCPegoraroEAngeliniCCiscatoPPrelleADecorin and biglycan expression is differentially altered in several muscular dystrophiesBrain200512825462555[PubMed][Google Scholar]
110. ZanottiSSarediSRuggieriAFabbriMBlasevichFRomaggiSMorandiLMoraMAltered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubesMatrix Biol200726615624[PubMed][Google Scholar]
111. MuchirAPavlidisPBonneGHayashiYKWormanHJActivation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery Dreifuss muscular dystrophyHum Mol Genet20071618841895[PubMed][Google Scholar]
112. MuchirAPavlidisPDecostreVHerronAJArimuraTBonneGWormanHJActivation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophyJ Clin Invest200711712821293[PubMed][Google Scholar]
113. GriffinMAFengHTewariMAcostaPKawanaMSweeneyHLDischerDEgamma-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesionJ Cell Sci200511814051416[PubMed][Google Scholar]
114. WoodmanSEParkDSCohenAWCheungMWChandraMShiraniJTangBJelicksLAKitsisRNChristGJCaveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascadeJ Biol Chem20022773898838997[PubMed][Google Scholar]
115. MarkertCDMeaneyMPVoelkerKAGrangeRWDalleyHWCannJKAhmedMBishwokarmaBWalkerSJYuSXFunctional muscle analysis of the Tcap knockout mouseHum Mol Genet20101922682283[PubMed][Google Scholar]
116. ChenYWNagarajuKBakayMMcIntyreORawatRShiRHoffmanEPEarly onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophyNeurology200565826834[PubMed][Google Scholar]
117. PorterJDKhannaSKaminskiHJRaoJSMerriamAPRichmondsCRLeahyPLiJGuoWAndradeFHA chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx miceHum Mol Genet200211263272[PubMed][Google Scholar]
118. VetroneSAMontecino-RodriguezEKudryashovaEKramerovaIHoffmanEPLiuSDMiceliMCSpencerMJOsteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-betaJ Clin Invest200911915831594[PubMed][Google Scholar]
119. ZanottiSGibertiniSMoraMAltered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatmentCell Tissue Res2010339397410[PubMed][Google Scholar]
120. SunGHaginoyaKWuYChibaYNakanishiTOnumaASatoYTakigawaMIinumaKTsuchiyaSConnective tissue growth factor is overexpressed in muscles of human muscular dystrophyJ Neurol Sci20082674856[PubMed][Google Scholar]
121. KumarAKhandelwalNMalyaRReidMBBoriekAMLoss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibersFASEB J200418102113[PubMed][Google Scholar]
122. KolodziejczykSMWalshGSBalazsiKSealePSandozJHierlihyAMRudnickiMAChamberlainJSMillerFDMegeneyLAActivation of JNK1 contributes to dystrophic muscle pathogenesisCurr Biol20011112781282[PubMed][Google Scholar]
123. NakamuraAHarrodGVDaviesKEActivation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin-dystrophin knockout miceNeuromuscul Disord200111251259[PubMed][Google Scholar]
124. VidalBSerranoALTjwaMSuelvesMArditeEDe MoriRBaeza-RajaBMartinez de LagranMLafustePRuiz-BonillaVFibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathwayGenes Dev20082217471752[PubMed][Google Scholar]
125. GoldsteinJAKellySMLoprestiPPHeydemannAEarleyJUFergusonELWolfMJMcNallyEMSMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophyHum Mol Genet2010[Google Scholar]
126. HayotMRodriguezJVernusBCarnacGJeanEAllenDGoretLObertPCandauRBonnieuAMyostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuliMol Cell Endocrinol20113323847[PubMed][Google Scholar]
127. LalaniRBhasinSByhowerFTarnuzzerRGrantMShenRAsaSEzzatSGonzalez-CadavidNFMyostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flightJ Endocrinol2000167417428[PubMed][Google Scholar]
128. AllenDLClearyASLindsaySFLohASReedJMMyostatin expression is increased by food deprivation in a muscle-specific manner and contributes to muscle atrophy during prolonged food deprivation in miceJ Appl Physiol2010109692701[PubMed][Google Scholar]
129. AllenDLMcCallGELohASMaddenMCMehanRSAcute daily psychological stress causes increased atrophic gene expression and myostatin-dependent muscle atrophyAm J Physiol Regul Integr Comp Physiol2010299R889898[PubMed][Google Scholar]
130. WehlingMCaiBTidballJGModulation of myostatin expression during modified muscle useFASEB J200014103110[PubMed][Google Scholar]
131. HeinemeierKMOlesenJLHaddadFSchjerlingPBaldwinKMKjaerMEffect of unloading followed by reloading on expression of collagen and related growth factors in rat tendon and muscleJ Appl Physiol2009106178186[PubMed][Google Scholar]
132. JonesSWHillRJKrasneyPAO'ConnerBPeirceNGreenhaffPLDisuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle massFASEB J20041810251027[PubMed][Google Scholar]
133. KimJWonKJLeeHMHwangBYBaeYMChoiWSSongHLimKWLeeCKKimBp38 MAPK participates in muscle-specific RING finger 1-Mediated atrophy in cast-immobilized rat gastrocnemius muscleKorean J Physiol Pharmacol200913491496[PubMed][Google Scholar]
134. ReardonKADavisJKapsaRMChoongPByrneEMyostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophyMuscle Nerve200124893899[PubMed][Google Scholar]
135. HiroseTNakazatoKSongHIshiiNTGF-beta1 and TNF-alpha are involved in the transcription of type I collagen alpha2 gene in soleus muscle atrophied by mechanical unloadingJ Appl Physiol2008104170177[PubMed][Google Scholar]
136. MachidaSBoothFWChanges in signalling molecule levels in 10-day hindlimb immobilized rat musclesActa Physiol Scand2005183171179[PubMed][Google Scholar]
137. CarlsonCJBoothFWGordonSESkeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloadingAm J Physiol1999277R601606[PubMed][Google Scholar]
138. CostelliPMuscaritoliMBonettoAPennaFReffoPBossolaMBonelliGDogliettoGBBaccinoFMRossi FanelliFMuscle myostatin signalling is enhanced in experimental cancer cachexiaEur J Clin Invest200838531538[PubMed][Google Scholar]
139. TanakaMMiyazakiHTakedaYTakeoSDetection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing miceCancer Lett1993726570[PubMed][Google Scholar]
140. HouiKKobayashiTKatoSMochioSInoueKIncreased plasma TGF-beta1 in patients with amyotrophic lateral sclerosisActa Neurol Scand2002106299301[PubMed][Google Scholar]
141. Gonzalez-CadavidNFTaylorWEYarasheskiKSinha-HikimIMaKEzzatSShenRLalaniRAsaSMamitaMOrganization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wastingProc Natl Acad Sci USA1998951493814943[PubMed][Google Scholar]
142. MaKMallidisCBhasinSMahabadiVArtazaJGonzalez-CadavidNAriasJSalehianBGlucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expressionAm J Physiol Endocrinol Metab2003285E363371[PubMed][Google Scholar]
143. RoubenoffRSarcopenia and its implications for the elderlyEur J Clin Nutr200054Suppl 3S4047[PubMed][Google Scholar]
144. MachidaSNarusawaMThe roles of satellite cells and hematopoietic stem cells in impaired regeneration of skeletal muscle in old ratsAnn N Y Acad Sci20061067349353[PubMed][Google Scholar]
145. CarlsonMEHsuMConboyIMImbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cellsNature2008454528532[PubMed][Google Scholar]
146. CarlsonMESuettaCConboyMJAagaardPMackeyAKjaerMConboyIMolecular aging and rejuvenation of human muscle stem cellsEMBO Mol Med20091381391[PubMed][Google Scholar]
147. LegerBDeraveWDe BockKHespelPRussellAPHuman sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylationRejuvenation Res200811163175B[PubMed][Google Scholar]
148. PuthuchearyZHarridgeSHartNSkeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategiesCrit Care Med201038S676682[PubMed][Google Scholar]
149. Di GiovanniSMolonABroccoliniAMelconGMirabellaMHoffmanEPServideiSConstitutive activation of MAPK cascade in acute quadriplegic myopathyAnn Neurol200455195206[PubMed][Google Scholar]
150. LavoiePRobitailleGAgharaziiMLedbetterSLebelMLariviereRNeutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic ratsJ Hypertens20052318951903[PubMed][Google Scholar]
151. LimDSLutucutaSBachireddyPYoukerKEvansAEntmanMRobertsRMarianAJAngiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathyCirculation2001103789791[PubMed][Google Scholar]
152. Rodriguez-VitaJSanchez-LopezEEstebanVRuperezMEgidoJRuiz-OrtegaMAngiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanismCirculation200511125092517[PubMed][Google Scholar]
153. HirataAMasudaSTamuraTKaiKOjimaKFukaseAMotoyoshiKKamakuraKMiyagoe-SuzukiYTakedaSExpression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontinAm J Pathol2003163203215[PubMed][Google Scholar]
154. PereiraROCarvalhoSNStumboACRodriguesCAPortoLCMouraASCarvalhoLOsteopontin expression in coculture of differentiating rat fetal skeletal fibroblasts and myoblastsIn Vitro Cell Dev Biol Anim20064247[PubMed][Google Scholar]
155. UaesoontrachoonKYooHJTudorEMPikeRNMackieEJPagelCNOsteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitroInt J Biochem Cell Biol20084023032314[PubMed][Google Scholar]
156. WagnerKRMcPherronACWinikNLeeSJLoss of myostatin attenuates severity of muscular dystrophy in mdx miceAnn Neurol200252832836[PubMed][Google Scholar]
157. GilsonHSchakmanOCombaretLLausePGrobetLAttaixDKetelslegersJMThissenJPMyostatin gene deletion prevents glucocorticoid-induced muscle atrophyEndocrinology2007148452460[PubMed][Google Scholar]
158. LiZFSheltonGDEngvallEElimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethalityAm J Pathol2005166491497[PubMed][Google Scholar]
159. McMahonCDPopovicLOldhamJMJeanplongFSmithHKKambadurRSharmaMMaxwellLBassJJMyostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspensionAm J Physiol Endocrinol Metab2003285E8287[PubMed][Google Scholar]
160. AmthorHMachariaRNavarreteRSchuelkeMBrownSCOttoAVoitTMuntoniFVrbovaGPartridgeTLack of myostatin results in excessive muscle growth but impaired force generationProc Natl Acad Sci USA200710418351840[PubMed][Google Scholar]
161. GentryBAFerreiraJAPhillipsCLBrownMHindlimb skeletal muscle function in myostatin-deficient miceMuscle Nerve2011434957[PubMed][Google Scholar]
162. MendiasCLBakhurinKIFaulknerJATendons of myostatin-deficient mice are small, brittle, and hypocellularProc Natl Acad Sci USA2008105388393[PubMed][Google Scholar]
163. PennaFCostamagnaDFanzaniABonelliGBaccinoFMCostelliPMuscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibitionPLoS One20105e13604[PubMed][Google Scholar]
164. WuWShanJBonneGWormanHJMuchirAPharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA geneBiochim Biophys Acta20101802632638[PubMed][Google Scholar]
165. MuchirAShanJBonneGLehnartSEWormanHJInhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type laminsHum Mol Genet200918241247[PubMed][Google Scholar]
166. WuWMuchirAShanJBonneGWormanHJMitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C geneCirculation20111235361[PubMed][Google Scholar]